Findings

What do systematic reviews say?

4 questions · 4 findings · 2 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 25%Moderate 3 · 75%High 0 · 0%

Griseofulvin vs azole

Adverse events · participants with confirmed toenail onychomycosis

Griseofulvin probably leads to higher adverse events compared with azole (moderate certainty).

1 finding from 1 review

Oral antifungal medication for toenail onychomycosis 2017 · Cochrane Headline outcomes only
RR 2.41 [1.56, 3.73]
2 studies · 143 participants
Moderate

Griseofulvin vs terbinafine

Adverse events · participants with confirmed toenail onychomycosis

Griseofulvin may leads to higher adverse events compared with terbinafine (low certainty).

1 finding from 1 review

Oral antifungal medication for toenail onychomycosis 2017 · Cochrane Headline outcomes only
RR 2.09 [1.15, 3.82]
2 studies · 100 participants
Low

Complete cure and adverse events for terbinafine vs griseofulvin

Severe adverse events · children with tinea capitis

Complete cure and adverse events for terbinafine showed no clear difference in severe adverse events compared with griseofulvin (moderate certainty).

1 finding from 1 review

Systemic antifungal therapy for tinea capitis in children 2016 · Cochrane Headline outcomes only
RR 0.97 [0.24, 3.88]
1 study · 1549 participants
Moderate

Complete cure and adverse events for terbinafine vs griseofulvin

Adverse events attributed to the study drugs · children with tinea capitis

Complete cure and adverse events for terbinafine showed no clear difference in adverse events attributed to the study drugs compared with griseofulvin (moderate certainty).

1 finding from 1 review

Systemic antifungal therapy for tinea capitis in children 2016 · Cochrane Headline outcomes only
RR 1.11 [0.79, 1.57]
1 study · 1549 participants
Moderate